Medical company Boston Scientific Corporation (NYSE:BSX) on Monday announced the acquisition of BTG plc (LSE:BTG).
Following the effectiveness of the scheme of arrangement, BTG became a wholly-owned subsidiary of Boston Scientific and BTG shares no longer trade on the London Stock Exchange.
In conjunction with the acquisition, the holders of BTG common shares will receive GBP8.40 in cash per share.
BTG reportedly develops and commercialises products used in minimally-invasive procedures targeting cancer and vascular diseases. Its three key businesses include the highly-differentiated Interventional Medicine portfolio of interventional oncology therapeutic technologies for patients with liver and kidney cancers, a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease as well as a specialty pharmaceutical business comprised of acute care antidotes to treat overexposure to certain medications and toxins.
In connection with obtaining the antitrust clearances and the BTG transaction, Boston Scientific expects to complete the sale of its global embolic microspheres portfolio of Embozene, Embozene TANDEM and ONCOZENE brands to Varian Medical Systems Inc in due course.
(USD1=GBP8.2)
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886